Compare MaxLinear Inc. Common Stock (MXL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MaxLinear Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? MaxLinear Inc. Common Stock trades at $76 (market cap $8.04B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, MaxLinear Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MaxLinear Inc. Common Stock for 3 Days and Repligen Corporation Common Stock for 0 Days on average.
| MXL | RGEN | |
|---|---|---|
Market Cap | $8.04B | $11.14B |
Volume | 2,554,408 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $128.03 | $194.57 |
52-Week Low | $13.05 | $102.87 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $8.12B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MaxLinear (MXL) trades at $88.64, down 0.39% on the day, with strong technical momentum indicated by bullish moving averages and key support at $87. The company shows impressive revenue growth with Q2 2026 EPS beating expectations at $0.35 versus $0.33, though profitability remains challenged with a -18.24% net income margin. Recent AI-focused product launches like Topaz™ PON chips and strong infrastructure demand position MXL for continued growth.
MXL presents a compelling growth story driven by AI infrastructure demand, with analyst consensus at Buy (64.7%) and $91.67 price target offering 3.4% upside. However, negative profitability metrics and cash flow concerns require careful monitoring. The stock's 50.7% September surge (Motley Fool, Oct 2) reflects optimism, but execution risks and valuation premium warrant cautious optimism for long-term investors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MaxLinear Inc. Common Stock
MaxLinear develops analog and mixed-signal semiconductors for connectivity, communications, industrial, and data center applications.
Read more on MXL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
